Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 1, 2014, Pages 39-43

  Jo, K W ^a   Lee, S D ^a   Kim, W S ^a   Kim, D S ^a   Shim, Tae Sun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Later generation fluoroquinolone; Multidrug resistant TB; Ofloxacin

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; LIVER ENZYME; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH KOREA; TERTIARY CARE CENTER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; REGISTER; TIME; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; QUINOLINES; REGISTRIES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84892619857     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0307     Document Type: Article

References (17)

1. Kim D H, Kim H J, Park S K, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008; 178: 1075-1082
2. Pantel A, Petrella S, Veziris N, et al. Extending the defi nition of the gyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fl uoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother 2012; 56: 1990-1996
3. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/ 2008.402. Geneva, Switzerland: WHO, 2008
4. Zhao B Y, Pine R, Domagala J, Drlica K. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquidmedia and in human macrophages. Antimicrob Agents Chemother 1999; 43: 661-666
5. Dong Y, Xu C, Zhao X, Domagala J, Drlica K. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 1998; 42: 2978-2984
6. Poissy J, Aubry A, Fernandez C, et al. Should moxifl oxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54: 4765-4771
7. Sirgel F A, Warren R M, Streicher E M, Victor T C, van Helden P D, Böttger E C. gyrA mutations and phenotypic susceptibility levels to ofl oxacin and moxifl oxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67: 1088-1093
8. World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision. WHO/HTM/TB/2013.2. Geneva, Switzerland: WHO, 2013. http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345-eng.pdf Accessed October 2013
9. National Tuberculosis Association. Diagnostic standards and classification of tuberculosis. New York, NY, USA: National Tuberculosis Association, 1961
10. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifl oxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 2001; 32 (Suppl): S16-S22
11. Pestova E, Millichap J J, Noskin G A, et al. Intracellular targets of moxifl oxacin: A comparison with other fl uoroquinolones. J Antimicrob Chemother 2000; 45: 583-590
12. Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, Murray M B. Treatment outcomes among patients with extensively drugresistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14
13. Lee J, Lee C H, Kim D K, et al. Retrospective comparison of levofl oxacin and moxifl oxacin on multidrug-resistant tuberculosis treatment outcomes. Korean J Intern Med 2011; 26: 153-159
14. Malik S, Willby M, Sikes D, Tsodikov O V, Posey J E. New insights into fl uoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLOS ONE 2012; 7: e39754
15. Park Y K, Park C H, Koh W J, et al. Cross resistance of fl uoroquinolone drugs on gyrA gene mutation in Mycobacterium tuberculosis. Tuberc Respir Dis (Korea) 2005; 59: 250-256
16. Cui Z, Wang J, Lu J, Huang X, Hu Z. Association of mutation patterns in gyrA/B genes and ofl oxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect Dis 2011; 11: 78
17. Veziris N, Martin C, Brossier F, Bonnaud F, Denis F, Aubry A. Treatment failure in a case of extensively drug resistant tuberculosis associated with selection of a gyrB mutant causing fl uoroquinolone resistance. Eur J Clin Microbiol Infect Dis 2007; 26: 423-425